Ian Reynolds manages Pew’s drug spending research initiative, which identifies policy options to help manage drug costs and ensure that patients have access to lifesaving treatments. Previously, he was an officer in Pew’s health group, where he led planning and development of new initiatives and coordinated the launch of projects.
Before joining Pew, Reynolds worked at Boston-based Community Catalyst to advance state and federal policies that improve conflict-of-interest standards in medicine and promote evidence-based practices. He also served as a Peace Corps volunteer in Turkmenistan, focusing on community health. Reynolds received a master of public health from Boston University and a bachelor’s degree from the University of Michigan.
Recent WorkView All
Under the Part D program, private prescription drug plans provide drug coverage to Medicare enrollees. These plans negotiate drug rebates and other discounts with pharmaceutical manufacturers, which reduce program costs and allow plans to compete for beneficiaries based on lowering premiums and patient out-of-pocket costs. However, the federal government is prohibited from negotiating drug prices... Read More
On Nov. 20, The Pew Charitable Trusts’ drug spending research initiative submitted comments to the Centers for Medicare & Medicaid Services in response to a request for information on a new direction for the Innovation Center. The comments discussed two areas where the Innovation Center could test prescription drug models with potential to increase competition, reduce costs to Medicare... Read More
Of the 41 million Medicare Part D beneficiaries in 2016 (approximately 7.5 million of whom were also eligible for Medicaid), 12 million received a low-income subsidy (LIS, also known as Extra Help). The LIS helps beneficiaries with limited incomes to pay their Part D premiums and any cost-sharing on drugs, including deductibles and copayments. This assistance comes from subsidies the federal... Read More